HC Wainwright Reiterates Buy Rating for Leap Therapeutics (NASDAQ:LPTX)

HC Wainwright restated their buy rating on shares of Leap Therapeutics (NASDAQ:LPTX) in a research note published on Friday morning,Benzinga reports. The firm currently has a $5.50 target price on the stock.

Leap Therapeutics Stock Performance

Shares of Leap Therapeutics stock opened at $2.78 on Friday. The stock’s fifty day moving average is $2.94 and its 200 day moving average is $2.57. The stock has a market cap of $71.17 million, a P/E ratio of -1.44 and a beta of 0.22. Leap Therapeutics has a one year low of $1.68 and a one year high of $5.00.

Institutional Trading of Leap Therapeutics

Several hedge funds have recently modified their holdings of LPTX. Valence8 US LP bought a new stake in shares of Leap Therapeutics in the 3rd quarter worth about $48,000. HighTower Advisors LLC purchased a new stake in Leap Therapeutics during the third quarter valued at approximately $65,000. Key Client Fiduciary Advisors LLC lifted its stake in shares of Leap Therapeutics by 13.0% in the 3rd quarter. Key Client Fiduciary Advisors LLC now owns 321,923 shares of the company’s stock valued at $827,000 after purchasing an additional 37,067 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Leap Therapeutics by 18.0% in the 3rd quarter. Geode Capital Management LLC now owns 329,291 shares of the company’s stock worth $847,000 after purchasing an additional 50,194 shares during the period. Finally, Marshall Wace LLP increased its position in shares of Leap Therapeutics by 268.2% during the 2nd quarter. Marshall Wace LLP now owns 79,758 shares of the company’s stock valued at $156,000 after purchasing an additional 58,094 shares during the last quarter. 30.46% of the stock is owned by hedge funds and other institutional investors.

About Leap Therapeutics

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.